| Reference |
|---|
Joung J, Kirchgatterer P, Singh A, Cho J, Nety S, Larson R, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022;13:1606 pubmed publisher |
Wang B, Kothambawala T, Wang L, Matthew T, Calhoun S, Saini A, et al. Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. Mol Cancer Ther. 2021;20:2483-2494 pubmed publisher |
Lee M, Shin E, Bae J, Cho Y, Lee J, Lee Y, et al. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Sci Rep. 2020;10:19429 pubmed publisher |
Landgraf K, Kloting N, Gericke M, Maixner N, Guiu Jurado E, Scholz M, et al. The Obesity-Susceptibility Gene TMEM18 Promotes Adipogenesis through Activation of PPARG. Cell Rep. 2020;33:108295 pubmed publisher |
Forde H, Harper E, Rochfort K, Wallace R, Davenport C, Smith D, et al. TRAIL inhibits oxidative stress in human aortic endothelial cells exposed to pro-inflammatory stimuli. Physiol Rep. 2020;8:e14612 pubmed publisher |
Woo S, Seo S, Kubatka P, Min K, Kwon T. Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation. Biomolecules. 2019;9: pubmed publisher |
Hong M, Li J, Li S, M Almutairi M. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation. Cells. 2019;8: pubmed publisher |
Kong W, Yee Z, Mai C, Fang C, Abdullah S, Ngai S. Zebularine and trichostatin A sensitized human breast adenocarcinoma cells towards tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis. Heliyon. 2019;5:e02468 pubmed publisher |
O Hara S, Splinter P, Trussoni C, Guicciardi M, Splinter N, Al Suraih M, et al. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. J Biol Chem. 2019;294:18698-18713 pubmed publisher |
Kim E, Jang J, Sung E, Song I, Kim J, Lee T. MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells. Int J Mol Sci. 2019;20: pubmed publisher |
Woo S, Min K, Seo S, Kim S, Kubatka P, Park J, et al. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma. Int J Mol Sci. 2019;20: pubmed publisher |
Jo E, Lee Y, Lee H, Park J, Park H, Choi Y, et al. Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells. BMC Cancer. 2019;19:496 pubmed publisher |
Li T, Yang Y, Song H, Li H, Cui A, Liu Y, et al. Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation manner. J Leukoc Biol. 2019;105:695-704 pubmed publisher |
Kim B, Park S, Jeong Y, Na Y, Kim J, Jo M, et al. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. Oncogene. 2019;38:3903-3918 pubmed publisher |
Tian S, Liu D, Wang D, Ren F, Xia P. Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression. Cell Physiol Biochem. 2018;51:217-227 pubmed publisher |
Hunt N, Lockwood G, Warren A, Mao H, McCourt P, Le Couteur D, et al. Manipulating fenestrations in young and old liver sinusoidal endothelial cells. Am J Physiol Gastrointest Liver Physiol. 2019;316:G144-G154 pubmed publisher |
Lian B, Yang D, Liu Y, Shi G, Li J, Yan X, et al. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis. Cell Physiol Biochem. 2018;49:2151-2162 pubmed publisher |
Williams C, Qazi U, Bernstein M, Charniak A, Gohr C, Mitton Fitzgerald E, et al. Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease. Osteoarthritis Cartilage. 2018;26:797-806 pubmed publisher |
Liang D, Huang W, Chang Q, Hou Y. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-κB dependent cFLIPL expression. PLoS ONE. 2018;13:e0191545 pubmed publisher |
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher |
Hong S, Min C, Jun Y, Lee D, Kim S, Park J, et al. Silencing of peroxiredoxin II by promoter methylation is necessary for the survival and migration of gastric cancer cells. Exp Mol Med. 2018;50:e443 pubmed publisher |
Woo S, Min K, Seo S, Kim S, Park J, Song D, et al. Up-regulation of 5-lipoxygenase by inhibition of cathepsin G enhances TRAIL-induced apoptosis through down-regulation of survivin. Oncotarget. 2017;8:106672-106684 pubmed publisher |
Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, et al. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Mol Cancer Res. 2018;16:378-389 pubmed publisher |
Yang J, Wu Y, Wang X, Xu L, Zhao X, Yang Y. Chemoresistance is associated with overexpression of HAX-1, inhibition of which resensitizes drug-resistant breast cancer cells to chemotherapy. Tumour Biol. 2017;39:1010428317692228 pubmed publisher |
Mitchell M, Webster J, Chung A, Guimarães P, Khan O, Langer R. Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun. 2017;8:14179 pubmed publisher |
Lee S, Hyun S, Kim H, Kang C, Kim S. Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL. Oncol Res. 2016;24:495-509 pubmed publisher |
Liang C, Xu Y, Li G, Zhao T, Xia F, Li G, et al. Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis. Onco Targets Ther. 2017;10:417-428 pubmed publisher |
You B, Han B, Park W. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. Oncotarget. 2017;8:17726-17737 pubmed publisher |
Baijer J, Déchamps N, Perdry H, Morales P, Kerns S, Vasilescu A, et al. TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis. Oncotarget. 2016;7:21416-27 pubmed publisher |
Lizarraga F, Ceballos Cancino G, Espinosa M, Vazquez Santillan K, Maldonado V, Melendez Zajgla J. Tissue Inhibitor of Metalloproteinase-4 Triggers Apoptosis in Cervical Cancer Cells. PLoS ONE. 2015;10:e0135929 pubmed publisher |
Jang J, Kim S, Cho E, Jeong S, Park E, Lee W, et al. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications. PLoS ONE. 2014;9:e98171 pubmed publisher |
Meng X, Koh B, Zhang J, Flatten K, Schneider P, Billadeau D, et al. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289:20543-58 pubmed |
Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, et al. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. Cell Stem Cell. 2014;14:592-605 pubmed publisher |
You B, Park W. Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels. Int J Oncol. 2014;44:1745-55 pubmed publisher |
Wehrkamp C, Gutwein A, Natarajan S, Phillippi M, Mott J. XIAP antagonist embelin inhibited proliferation of cholangiocarcinoma cells. PLoS ONE. 2014;9:e90238 pubmed publisher |
Kim S, Woo J, Jeong C, Ryu C, Jang J, Jeun S. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med. 2014;3:172-82 pubmed publisher |
Tatsuta T, Hosono M, Takahashi K, Omoto T, Kariya Y, Sugawara S, et al. Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL. Int J Oncol. 2014;44:377-84 pubmed publisher |
Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, et al. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res. 2014;12:217-27 pubmed publisher |
De Chiara A, Pederzoli Ribeil M, Mocek J, Candalh C, Mayeux P, Millet A, et al. Characterization of cytosolic proliferating cell nuclear antigen (PCNA) in neutrophils: antiapoptotic role of the monomer. J Leukoc Biol. 2013;94:723-31 pubmed publisher |
Akimoto K, Kimura K, Nagano M, Takano S, To a Salazar G, Yamashita T, et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev. 2013;22:1370-86 pubmed publisher |
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher |
Sagiv A, Biran A, Yon M, Simon J, Lowe S, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene. 2013;32:1971-7 pubmed publisher |
Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 2011;17:3181-92 pubmed publisher |
Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011;17:1741-52 pubmed publisher |
Park S, Kim M, Kim H, Sohn H, Bae J, Kang C, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol. 2009;77:1328-36 pubmed publisher |
Inglefield J, Dumitru C, Alkan S, Gibson S, Lipson K, Tomai M, et al. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res. 2008;28:253-63 pubmed publisher |
Chamoux E, Houde N, L Ériger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008;216:536-42 pubmed publisher |
Locklin R, Federici E, Espina B, Hulley P, Russell R, Edwards C. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007;6:3219-28 pubmed |
Dumitru C, Gulbins E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene. 2006;25:5612-25 pubmed |
Cross S, Yang Z, Brown N, Balasubramanian S, Evans C, Woodward J, et al. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?. Int J Cancer. 2006;118:1901-8 pubmed |
